Drug intelligence / Profile preview

autologous adipose-derived mesenchymal stem cells (Gülhane)

Development stage
Unknown
Lead developer
Gulhane School of Medicine
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intravenous, Intra-arterial
01

Overview

Autologous adipose-derived mesenchymal stem cells (AD-MSCs) are an investigational cell therapy developed by Saglik Bilimleri Universitesi Gulhane Tip Fakultesi for the treatment of liver cirrhosis secondary to chronic Hepatitis C virus (HCV) infection. The therapy involves harvesting mesenchymal stem cells from the patient's own adipose tissue, followed by expansion and repeated re-infusion. The treatment protocol utilizes a dual-route administration: a portion of the cells is delivered intravenously via a peripheral vein, while a larger dose is administered directly into the right hepatic artery. The therapeutic rationale is based on the ability of MSCs to migrate to damaged liver tissue and exert immunomodulatory, anti-inflammatory, and pro-regenerative effects, potentially promoting hepatocyte regeneration and reducing fibrosis as an alternative to liver transplantation.

Other names
AD-MSCsautologous adipose-derived mesenchymal stem cellsadipose tissue-derived autologous mesenchymal stem cells

Beyond the preview

Go deeper on autologous adipose-derived mesenchymal stem cells (Gülhane).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous adipose-derived mesenchymal stem cells (Gülhane).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call